Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole in neonates and preterm infants with presumed gastroesophageal reflux disease
NL-OMON30569Phase 3Not yet recruiting
- Sponsor
- Wyeth
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Wyeth. Primary endpoints: Single-dose pharmacokinetics, Multiple-dose pharmacokinetics and accumulation and 1 more. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON30569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30569.